Neuroblastoma

Electrify Expo and Volvo Cars Team Up to Support Alex’s Lemonade Stand Foundation in the Fight Against Childhood Cancer

Retrieved on: 
fredag, maj 31, 2024
Partnership, EV, Volvo, Neuroblastoma, Alex's Lemonade Stand Foundation, Mother, Travel, Sale, Electrification, Believer, Research, Cancer, Lemonade, Movement, Car, Rail transport

LONG BEACH, Calif., May 31, 2024 (GLOBE NEWSWIRE) -- Electrify Expo , North America’s largest electric vehicle (EV) festival, has partnered with Swedish car brand Volvo Cars to support Alex’s Lemonade Stand Foundation (ALSF), an American pediatric cancer 501(c)(3) nonprofit organization.

Key Points: 
  • LONG BEACH, Calif., May 31, 2024 (GLOBE NEWSWIRE) -- Electrify Expo , North America’s largest electric vehicle (EV) festival, has partnered with Swedish car brand Volvo Cars to support Alex’s Lemonade Stand Foundation (ALSF), an American pediatric cancer 501(c)(3) nonprofit organization.
  • “We are so honored to be included in the Electrify Expo as part of our longstanding partnership with Volvo,” says Liz Scott, Alex's Mom and co-executive director at Alex's Lemonade Stand Foundation.
  • “Volvo Cars has been a believer in Alex’s Lemonade Stand Foundation since we pledged to help Alex reach her million-dollar goal over 20 years ago,” said Mike Cottone, President, Volvo Car USA and Canada.
  • You can support ALSF with Electrify Expo and Volvo by purchasing an EE ticket as a percentage of sales will go to ALSF, or hosting your own lemonade stand, or donating directly to help the cause at https://www.alexslemonade.org

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Retrieved on: 
onsdag, maj 29, 2024
Patient, Infection, Mesothelioma, Neuroblastoma, Measles, Human, Toxicity, Science, HPV, RNA, Clinical trial, Fruit, Vaccine, Research, Potyvirus, Pasteur Institute, Virus, GMP

Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.

Key Points: 
  • Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.
  • Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of new vaccines based on MeasovirR technology, based on the measles vaccine virus.
  • The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate   the first clinical trial.
  • The joint Institut Pasteur - Oncovita laboratory will also be carrying out research into viral defective interfering RNAs (DI-RNAs) produced by modified recombinant measles viruses.

Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

Retrieved on: 
tisdag, maj 21, 2024
Genetic engineering, Apolipoprotein, Doctor of Philosophy, Gene editing, DNA, Neuroblastoma, Risk, Aneuploidy, FITC, FDA, Disease, Federal Medical Centres, Safety, SAN, Publication, CB, APOE, OGM, Research, European Central Bank, SVS, Workflow, Culture, Quality control, Hospital, Genomics, B cell, Genotype, Canadian Aviation Regulations, PB, Vaccine

Study results confirmed the vulnerability of genomic DNA to gene editing and highlighted the utility of OGM for genome-wide quality assessment of genetic engineering.

Key Points: 
  • Study results confirmed the vulnerability of genomic DNA to gene editing and highlighted the utility of OGM for genome-wide quality assessment of genetic engineering.
  • “These studies highlight how researchers can use OGM when developing cell and gene therapies.
  • The expansion of gene therapy faces risks due to both on-target and off-target structural variations that may be introduced during genome editing.
  • To learn more about OGM’s utility in cell and gene therapy applications, please visit this website .

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Retrieved on: 
onsdag, maj 15, 2024
Doxorubicin, Patient, Doctor of Philosophy, Survival, Neuroblastoma, CPP, PBLA, AACR, Therapy, Overalls, Growth, Research, Topotecan, Note, Acquisition, Cyclophosphamide, Data analysis, Celecoxib, Loss, MSN, DFMO, OTCQB, Pharmaceutical industry

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024.

Key Points: 
  • MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024.
  • Q1 2024 and recent Highlights:
    Announced revised timing for the interim data analysis for its ongoing ASPIRE trial, evaluating ivospemin (SBP-101) in combination with standard-of-care for metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • On the financial and business front, we announced the transfer of our common stock to the OTCQB market and successfully closed a $9.0 million public offering.
  • Net proceeds from the raise, which closed on January 31, 2024, were approximately $8.1 million.

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
tisdag, maj 14, 2024
Rhabdomyosarcoma, Patient, Bangladesh Technical Education Board, MDS, Neuroblastoma, University, Acute lymphoblastic leukemia, Ovarian cancer, B-ALL, RNA polymerase II, Venetoclax, Lymphoid leukemia, MCL, TFL, Oncogene, AACR, IND, CDK9, CPT, Prednisone, Lymphoma, Neoplasm, Safety, ADC, CLL, SMDC, PRS, Blood, AML, PTCL, Spacecraft, Cancer, MYC, Myelodysplastic syndrome, RNA, Research, DLBCL, Therapy, MCL1, NIH, Annual general meeting, Pharmaceutical industry

PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter of 2024 and provided a corporate update.

Key Points: 
  • “Our recent financing provides capital to support the dose-escalation studies for our potentially best-in-class ADC, VIP943, and first-in-class SMDC, VIP236.
  • Vincerx looks forward to sharing additional Phase 1 data by the end of Q3 2024.
  • For the first quarter ended March 31, 2024, Vincerx reported a net loss of approximately $12.4 million, or $0.58 per share.
  • For the first quarter ended March 31, 2023, Vincerx reported a net loss of approximately $14.6 million, or $0.69 per share.

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Retrieved on: 
tisdag, april 9, 2024
Survival, Immunotherapy, Neuroblastoma, Patient, Journal, EFS, Acquisition, Jazz Pharmaceuticals, Cancer, Radiation, Haematopoietic system, Pharmaceutical industry

This will be Essential’s first clinical development-stage asset and is targeted at addressing significant unmet needs in paediatric oncology patients.

Key Points: 
  • This will be Essential’s first clinical development-stage asset and is targeted at addressing significant unmet needs in paediatric oncology patients.
  • Simon Ball, CEO and co-founder of Renaissance Pharma, who has significant scientific and commercial expertise within the space, will continue to work with Essential Pharma on Hu14.18’s development, as will many of the Renaissance Pharma team.
  • Approximately half of all neuroblastoma patients have high risk (HRNB) disease which has an overall survival of ~50% over five years23.
  • Essential Pharma will be responsible for clinical development and defining the optimal route for regulatory approval and eventual commercial launch of Hu14.18.

Lirum Therapeutics to Present Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against Adult and Pediatric IGF-Related Cancers, at the 2024 AACR Annual Meeting

Retrieved on: 
torsdag, april 4, 2024
Malignancy, Head, Neuroblastoma, Section 23, Breast, Sarcoma, AACR, Therapy, Cancer, Poster, Neck

Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement.

Key Points: 
  • Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement.
  • In particular, these malignancies have known genetic alterations affecting the IGF-1R pathway and/or high IGF-1R expression tied to poor outcomes.
  • Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway.
  • Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.

ibex Sponsors 2024 Caitlin Robb Foundation Golf Tournament

Retrieved on: 
torsdag, april 4, 2024
Organization, BPO, Memory, Neuroblastoma, Ibex, Research, Delaware Valley, Life

WASHINGTON, April 04, 2024 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced its sponsorship of the 2024 Caitlin Robb Foundation Golf Tournament happening on Friday, April 5, at the Papago Golf Club in Phoenix.

Key Points: 
  • WASHINGTON, April 04, 2024 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced its sponsorship of the 2024 Caitlin Robb Foundation Golf Tournament happening on Friday, April 5, at the Papago Golf Club in Phoenix.
  • “We are proud to continue to support the Caitlin Robb Foundation and the ground-breaking pediatric cancer research it funds,” said ibex CEO Bob Dechant.
  • “Honoring the life of Caitlin Robb through this tournament is a special way to help bring awareness to cancer research and help us find a cure.”
    The Caitlin Robb Foundation was founded in 1995 by the Robb Family and caring friends, named in memory of a two-year-old Tempe, Arizona toddler who lost a courageous battle earlier that year against neuroblastoma, the most common extracranial solid-tumor pediatric cancer.
  • “We appreciate the dedication of ibex as an Event Sponsor of the Caitlin Robb Foundation’s annual golf tournament for the eighth year in a row,” added Jack Jones, ibex Board Member and founder of the Caitlin Robb Foundation Delaware Valley Chapter.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
onsdag, mars 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

Retrieved on: 
tisdag, mars 26, 2024
Research, Topotecan, PBLA, Neuroblastoma, Patient, Data monitoring committee, Acquisition, Celecoxib, Doctor of Philosophy, AACR, MSN, CPP, Pancreatic cancer, Therapy, DSMB, Poster, DFMO, Cyclophosphamide, Pharmaceutical industry

MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
  • “Looking ahead, Panbela remains unwavering in its commitment to patients and in its pursuit of maximizing value for stockholders.
  • Notes payable, plus accrued interest, on the balance sheet, the result of the acquisition of CPP, totaled approximately $5.4 million.
  • Gross proceeds from the raise, which closed on January 31, 2024, were approximately $9 million.